GlassScriptPhysician profile
Ivan Mikolaenko
NPI 1023231883
$22,557.89
in general payments reported to CMS, 2019-2025
62 companies · $7,401 in 2025
The $7,401 reported for 2025 was more than what 88% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $2,290 · 2023: $5,374 · 2024: $7,492 · 2025: $7,401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $20K · Education: $253 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $19,991.60 |
| Education | $253.05 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,131.57 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,850.27 | 2023-2025 | Rexulti, Nuedexta |
| Sk Life Science, INC. | $1,495.22 | 2022-2025 | Xcopri |
| Axsome Therapeutics, INC. | $1,174.83 | 2023-2025 | Auvelity, Symbravo, Sunosi |
| Ucb, INC. | $959.03 | 2022-2025 | Briviact, Fintepla, Nayzilam |
| Pfizer INC. | $826.45 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $810.14 | 2022-2025 | Austedo Xr, Austedo, Ajovy |
| Neurelis, INC. | $715.94 | 2022-2025 | Valtoco |
| Lundbeck LLC | $677.34 | 2023-2025 | Vyepti, Rexulti |
| Scilex Pharmaceuticals INC. | $630.84 | 2022-2025 | Ztlido |
| Biogen, INC. | $600.57 | 2022-2025 | Vumerity, Tysabri, Leqembi |
| Amneal Pharmaceuticals LLC | $559.30 | 2022-2025 | Crexont, Rytary, Ongentys |
| Amgen INC. | $489.97 | 2022-2025 | Uplizna |
| Kyowa Kirin, INC. | $460.79 | 2022-2025 | Nourianz |
| Takeda Pharmaceuticals U.S.A., INC. | $443.80 | 2022-2025 | Trintellix, Hyqvia |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $400.97 | 2022-2025 | Nuplazid |
| Neurocrine Biosciences, INC. | $379.61 | 2022-2025 | Ingrezza |
| Azurity Pharmaceuticals, INC. | $356.56 | 2023-2025 | Horizant, Horizant |
| Lilly USA, LLC | $317.66 | 2022-2025 | Amyvid, Emgality, Reyvow |
| Mdd US Operations, LLC | $288.46 | 2024-2025 | Gocovri |
| Argenx US, INC. | $278.57 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Eisai INC. | $273.16 | 2023-2025 | |
| Kowa Pharmaceuticals America, INC. | $251.83 | 2023 | Seglentis |
| Harmony Biosciences LLC | $250.40 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $235.10 | 2024-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $226.22 | 2022 | |
| Genentech USA, INC. | $174.12 | 2022-2025 | Ocrevus, Ocrevus Zunovo |
| Acorda Therapeutics, INC | $170.57 | 2022-2024 | Inbrija |
| Boston Scientific Corporation | $157.90 | 2024 | |
| Ani Pharmaceuticals, INC. | $138.72 | 2024-2025 | Purified Cortrophin Gel |
| 4web, INC. | $134.97 | 2024 | Spine Truss System |
| Alkermes, INC. | $125.87 | 2025 | Lybalvi |
| Mallinckrodt Hospital Products INC. | $125.00 | 2025 | Acthar |
| Genzyme Corporation | $119.99 | 2022 | |
| Merck Sharp & Dohme LLC | $118.37 | 2023-2024 | Verquvo, Belsomra |
| Novartis Pharmaceuticals Corporation | $115.17 | 2025 | |
| Merz Pharmaceuticals, LLC | $99.79 | 2025 | Xeomin, Inbrija |
| Alexion Pharmaceuticals, INC. | $86.06 | 2023-2025 | Ultomiris |
| Vanda Pharmaceuticals INC. | $81.36 | 2024 | Ponvory |
| Almatica Pharma LLC | $74.06 | 2022-2023 | Gralise |
| Abbott Laboratories | $65.81 | 2022-2025 | Aveir, Infinity |
| Medtronic, INC. | $60.00 | 2022 | |
| Forte Bio-Pharma LLC | $59.16 | 2025 | Prolate, Tanlor, Nalocet |
| Supernus Pharmaceuticals, INC. | $49.47 | 2024-2025 | Qelbree |
| Arbor Pharmaceuticals, INC. | $48.79 | 2022 | |
| Sumitomo Pharma America, INC. | $45.59 | 2023 | Aptiom |
| Bausch Health US, LLC | $44.81 | 2022 | |
| Impel Pharmaceuticals INC. | $37.96 | 2022-2023 | Trudhesa |
| Catalyst Pharmaceuticals, INC. | $36.87 | 2023 | Firdapse |
| Csl Behring | $35.83 | 2024-2025 | Hizentra, Privigen |
| Impel Pharmaceuticals LLC | $30.44 | 2025 | Trudhesa |
| Corium, LLC | $25.00 | 2024 | Azstarys |
| Altathera Pharmaceuticals LLC | $24.59 | 2023 | Sotalol Hydrochloride |
| Avanir Pharmaceuticals, INC. | $23.95 | 2022 | |
| Celgene Corporation | $23.88 | 2025 | Zeposia |
| Jazz Pharmaceuticals INC. | $23.84 | 2025 | |
| Idorsia Pharmaceuticals US INC | $21.00 | 2023 | Quviviq |
| Nevro Corp. | $20.99 | 2022 | |
| Xeris Pharmaceuticals, INC. | $20.76 | 2024 | Keveyis |
| Astrazeneca Pharmaceuticals LP | $19.46 | 2023 | |
| Inspire Medical Systems, INC. | $18.26 | 2025 | Inspire |
| Horizon Therapeutics Plc | $14.88 | 2023 | Uplizna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivan Mikolaenko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.